학술논문
BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA
Document Type
Article
Author
Gonzalez, Victor H.; Luo, Caesar; Almeida, David R.P.; Cutino, Antonio; Coughlin, Brandon; Kasper, Jonathan; Kiernan, Daniel F.; Abdelsalam, Ahmed; Shakoor, Akbar; Moshiri, Ala; Barkmeier, Andrew; Tewari, Asheesh; Baker, Carl; Kiernan, Daniel; Rosberger, Daniel; Roth, Daniel; Eichenbaum, David; Malik, Deepika; Marcus, Dennis; Dehning, Doug; Reichel, Elias; Tilton, Elisha; Fu, Evelyn; Kokame, Gregg; Salehi-Had, Hani; Bhatt, Harit; Nielsen, Jared; Prensky, Jay; Lim, Jennifer; Adleberg, Jon; Beck, Joseph; Gunn, Joseph; Podhorzer, Joseph; Small, Kent; Kooragayala, Lakshmana; Freisberg, Lars; Schocket, Lisa; Berrocal, Maria; Worrall, Martin; Cassell, Michael; Singer, Michael; Tsipursky, Michael; Holekamp, Nancy; Weber, Pamela; Merrill, Pauline; Campochiaro, Peter; Dugel, Pravin; Khurana, Rahul; Apte, Rajendra; Rathod, Rajiv; Katz, Randy; Chace, Richard; Kwun, Robert; Grigorian, Ruben; Mansour, Sam; Chexal, Saradha; Madreperla, Steven; Gonzalez, Victor; Aldred, William
Source
Retina; August 2023, Vol. 43 Issue: 8 p1301-1307, 7p
Subject
Language
ISSN
0275004X; 15392864
Abstract
In this analysis of a 36-month, Phase 4, open-label, observational study, the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant helped maintain BCVA and reduce intraocular pressure–related events in eyes with better baseline BCVA, whereas retinal thickness variability and treatment burden decreased regardless of baseline BCVA.